VCRE (Vicore Pharma Holding AB) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 07, 2026)


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $15.03
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB 5-Year Yield-on-Cost %?

Vicore Pharma Holding AB VCRE -7.54% 13 5-Year Yield-on-Cost % is 0.00 as of Jul. 07, 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 152 Biotechnology companies, Vicore Pharma Holding AB ranks worse than 657894.08% on this metric.

Vicore Pharma Holding AB's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Vicore Pharma Holding AB's 5-Year Yield-on-Cost % or its related term are showing as below:



VCRE's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.665
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Vicore Pharma Holding AB  (NAS:VCRE) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Vicore Pharma Holding AB 5-Year Yield-on-Cost % Related Terms

VCRE vs : 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's 5-Year Yield-on-Cost % falls into.


VCRE
13GF Score
Vicore Pharma Holding AB VCRE
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Vicore Pharma Holding AB is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Vicore Pharma Holding AB (VCRE) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vicore Pharma Holding AB and its competitors. According to the industry distribution chart, Vicore Pharma Holding AB ranks #999999 out of 152 companies in the Biotechnology industry.
Is Vicore Pharma Holding AB's 5-Year Yield-on-Cost % too high?
Vicore Pharma Holding AB's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Vicore Pharma Holding AB ranks #999999 out of 152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's 5-Year Yield-on-Cost % compare to ?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #999999 out of 152 companies for 5-Year Yield-on-Cost %. This places Vicore Pharma Holding AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.67, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vicore Pharma Holding AB and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicore Pharma Holding AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.03
Price